Summary

The global Fecal Calprotectin Assays market is projected to grow from US$ 218 million in 2025 to US$ 387 million by 2032, at a CAGR of 8.5% (2026-2032), driven by critical product segments and diverse end‑use applications.
Fecal Calprotectin Assays are in vitro diagnostic reagents designed to qualitatively, semi-quantitatively or quantitatively detect calprotectin in human stool specimens as a non-invasive biomarker of intestinal inflammation. Commercial products are primarily based on enzyme linked immunosorbent assay, immunoturbidimetric assay, chemiluminescent immunoassay, fluorescence immunoassay and lateral flow immunochromatographic technologies, with quantitative laboratory assays representing an important form of routine clinical testing. Product configurations range from microplate reagent kits and analyzer-specific reagent packs to rapid test cassettes and fluorescence-based point-of-care formats, and commonly incorporate dedicated calibrators, controls and stool extraction systems. Fecal Calprotectin Assays are principally used in the initial evaluation of suspected inflammatory bowel disease, differentiation of inflammatory bowel disease from functional gastrointestinal disorders such as irritable bowel syndrome, and ongoing management of established Crohn’s disease and ulcerative colitis, including disease activity assessment, treatment-response monitoring and relapse-risk evaluation. The market therefore combines centralized laboratory immunodiagnostics with increasingly automated and rapid-testing workflows across gastroenterology and clinical laboratory settings.
Key Findings
Quantitative assays represent the principal commercial format across centralized laboratory and automated testing workflows
Europe has the highest concentration of established fecal calprotectin assay manufacturers and specialist diagnostic suppliers
The competitive structure combines multinational IVD groups with specialist gastrointestinal diagnostics companies and regional POCT manufacturers
Market Trends
The Fecal Calprotectin Assays market is shifting from conventional manual ELISA workflows toward faster and more automated testing formats. Immunoturbidimetric assays are increasingly integrated into routine clinical chemistry analyzers, while chemiluminescent and fluorescence immunoassays enable higher-throughput or shorter-turnaround testing. At the same time, lateral flow products are evolving from visually interpreted qualitative tests toward reader-assisted quantitative and semi-quantitative formats. Product development is increasingly focused on broader analytical ranges, improved stool extraction consistency, reduced hands-on time and compatibility with existing laboratory platforms. These changes are gradually positioning fecal calprotectin as a more standardized routine biomarker rather than a specialist test limited to dedicated gastroenterology laboratories.
Market Dynamics
Drivers
Growth is supported by the expanding clinical use of non-invasive intestinal inflammation biomarkers in inflammatory bowel disease pathways. Fecal calprotectin testing can reduce unnecessary invasive diagnostic procedures in selected patients, support differentiation between inflammatory and functional gastrointestinal disorders, and provide repeatable monitoring for established Crohn’s disease and ulcerative colitis. Increasing adoption of treat-to-target disease management, greater use of biologic therapies and the need for objective follow-up biomarkers further support recurrent testing demand. Automation on mainstream chemistry and immunoassay platforms is also lowering workflow barriers for general clinical laboratories.
Restraints
Market expansion is constrained by variability in assay-specific reference ranges, cut-off interpretation and pre-analytical stool handling. Different extraction devices, analytical platforms and calibration systems may generate results that are not fully interchangeable, limiting standardization across institutions. In addition, fecal calprotectin is a marker of intestinal inflammation rather than a disease-specific biomarker, so elevated values may require additional clinical assessment. Price pressure from high-volume laboratory tenders and lower-cost rapid-test manufacturers can also compress reagent ASPs, particularly in mature and emerging markets with increasing supplier competition.
Opportunities
The strongest opportunities lie in wider integration of fecal calprotectin into routine IBD monitoring pathways and expansion beyond specialist gastroenterology centers. Automated immunoturbidimetric and chemiluminescent products can penetrate medium- and high-throughput laboratories that already operate compatible analyzers, while fluorescence and reader-based rapid tests can extend access to outpatient and decentralized settings. Emerging markets also offer room for increased penetration as awareness of IBD rises and laboratories shift from outsourced testing toward local testing. Further opportunities exist in digital patient monitoring, where home sample collection or near-patient testing may be linked with longitudinal disease-management programs.
Challenges
Long-term challenges include achieving stronger harmonization between assay systems, improving consistency of stool extraction and maintaining clinically meaningful cut-offs across different patient populations. Manufacturers also face the need to balance analytical performance with lower testing costs as laboratories consolidate purchasing volumes. Competition is intensifying as established gastrointestinal diagnostics specialists, multinational IVD companies and Asian POCT manufacturers increasingly address the same clinical workflow. Maintaining differentiation therefore depends on platform compatibility, automation, analytical range, turnaround time, clinical evidence and the ability to secure long-term laboratory adoption.
Industry Chain Analysis
The upstream segment of the Fecal Calprotectin Assays industry mainly comprises monoclonal and polyclonal antibody suppliers, recombinant antigen and calibrator producers, immunoassay membranes, latex particles, enzymes, chemiluminescent substrates, fluorescence labels, buffers, plastics and stool extraction components. These materials are converted by IVD manufacturers into ELISA kits, immunoturbidimetric reagents, analyzer-specific chemiluminescent packs, fluorescence test devices and lateral flow cassettes. Product value is created through antibody performance, assay calibration, analytical validation, manufacturing consistency, regulatory registration and platform integration rather than through raw material cost alone.
The downstream segment consists primarily of hospital laboratories, independent clinical laboratories, gastroenterology centers and selected decentralized testing settings. Automated products generate value through laboratory throughput and reduced manual handling, while rapid formats compete through turnaround time and accessibility. Reagents are recurring consumables, so installed analyzer access, distributor coverage, clinician familiarity and repeat-testing frequency are important determinants of lifetime customer value. Stool extraction systems and dedicated consumables can strengthen supplier lock-in but remain secondary to the core assay reagent economics.
Segment Insights
By assay principle, the market is structurally divided among enzyme linked immunosorbent assays, immunoturbidimetric assays, chemiluminescent immunoassays, fluorescence immunoassays and lateral flow immunochromatographic assays. ELISA remains an established reference format with broad manufacturer participation, while immunoturbidimetric testing has gained importance because it can be integrated into routine chemistry workflows and processed at higher throughput. Chemiluminescent assays strengthen automation within immunodiagnostic laboratories, whereas fluorescence and lateral flow formats address rapid and decentralized testing needs.
By result format, quantitative assays form the core of clinical disease management because serial numerical values support assessment of inflammatory activity and response to therapy. Semi-quantitative and qualitative products remain relevant in rapid screening and lower-complexity testing environments, particularly where analyzer infrastructure is limited. The market is therefore moving toward higher automation and quantitative output while maintaining a distinct role for simpler rapid-testing formats.
Downstream Market Opportunities
The largest long-term clinical opportunity remains management of established inflammatory bowel disease, where repeated testing can support disease activity assessment, treatment-response monitoring and relapse-risk evaluation without repeated invasive procedures. Initial evaluation of patients with persistent gastrointestinal symptoms is another important demand source, particularly when clinicians need to distinguish probable inflammatory disease from functional disorders before referring patients for endoscopy. Wider adoption in outpatient gastroenterology, community laboratories and decentralized testing could increase testing frequency while shortening the interval between clinical symptoms and objective inflammatory assessment.
Regional Insights
Europe represents the most developed supplier cluster for Fecal Calprotectin Assays, with a dense concentration of specialist gastrointestinal diagnostics companies in Switzerland, Germany, Italy, Spain, Norway, Belgium, France and other European markets. The region benefits from established IBD management pathways, broad laboratory familiarity with fecal calprotectin and a diverse mix of ELISA, immunoturbidimetric, chemiluminescent and rapid-testing suppliers. North America is characterized by strong participation from multinational IVD groups and established specialist suppliers, with automation and regulatory clearance remaining important competitive factors.
Asia-Pacific is developing through a combination of established Japanese and Korean manufacturers and a growing Chinese POCT and immunodiagnostics manufacturing base. Japan has differentiated automated fecal-testing platforms, while China has expanded rapidly across fluorescence immunoassay, lateral flow, immunoturbidimetric and chemiluminescent formats. India has a smaller but identifiable domestic manufacturing base. Southeast Asia and Taiwan remain more dependent on imported products and regional distribution networks, creating opportunities for both international manufacturers and cost-competitive Asian suppliers.
Competitive Landscape Analysis
The competitive landscape is moderately fragmented and includes both multinational IVD groups and highly specialized gastrointestinal diagnostics manufacturers. BÜHLMANN Laboratories is a major specialist participant with ELISA, immunoturbidimetric and rapid quantitative solutions, while DiaSorin, Phadia under Thermo Fisher Scientific, Inova Diagnostics under Werfen, EIKEN CHEMICAL and Revvity-related businesses compete through automated immunodiagnostic or fecal-testing platforms. Specialist manufacturers including R-Biopharm, EUROSPITAL, Sentinel CH, Calpro, ALPCO, ORGENTEC, BioSystems and Immundiagnostik maintain strong positions in defined assay technologies or regional laboratory channels. Asian manufacturers including Boditech Med, Getein Biotech, Hangzhou AllTest, Xiamen Wiz Biotech, Sichuan Orienter and Agappe Diagnostics broaden competition in fluorescence immunoassay, rapid testing and cost-sensitive markets. Competitive differentiation increasingly depends on assay standardization, analytical range, compatibility with installed analyzers, stool extraction workflow, regulatory coverage and the ability to support recurrent testing programs rather than on reagent price alone.
Report Scope
This definitive report equips business leaders, decision-makers, and stakeholders with a 360° view of the global Fecal Calprotectin Assays market, seamlessly integrating production and sales performance across the value chain. It analyzes historical sales volume and revenue sales data (2021–2025) and delivers forecasts through 2032, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies volume and value, growth rates, technical innovations, niche opportunities, and substitution risks, and analyzes downstream customer distribution pattern.
Granular regional insights cover five major markets (North America, Europe, APAC, South America, and MEA) with in‑depth analysis of 20+ countries. Each region’s dominant products, competitive landscape, and downstream demand trends are clearly detailed.
Critical competitive intelligence profiles manufacturers (sales volume, revenue, margins, pricing strategies, and major customers) and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise supply‑chain overview maps upstream suppliers, manufacturing technologies, cost structures, and distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation
By Company
BÜHLMANN Laboratories AG
DiaSorin S.p.A.
Phadia AB
Inova Diagnostics, Inc.
EIKEN CHEMICAL CO., LTD.
Revvity, Inc.
R-Biopharm AG
EUROSPITAL S.p.A.
SENTINEL CH. SpA
Calpro AS
ALPCO
ORGENTEC Diagnostika GmbH
BioSystems S.A.
Boditech Med Inc.
Getein Biotech, Inc.
Hangzhou AllTest Biotech Co., Ltd.
Xiamen Wiz Biotech Co., Ltd.
Sichuan Orienter Bioengineering Co., Ltd.
Agappe Diagnostics Ltd.
Immundiagnostik AG
Alfresa Pharma Corporation
DiaSource ImmunoAssays S.A.
Epitope Diagnostics, Inc.
ScheBo Biotech AG
Vitassay Healthcare, S.L.U.
Certest Biotec S.L.
VEDA.LAB
Shijiazhuang Hipro Biotechnology Co., Ltd.
Guangzhou Forreal Biotechnology Co., Ltd.
AccuBioTech Co., Ltd.
Zhejiang Wantaifu Biotechnology Co., Ltd.
Famid Biomedical Technology Tianjin Co., Ltd.
Segment by Type
Enzyme Linked Immunosorbent Assay
Immunoturbidimetric Assay
Chemiluminescent Immunoassay
Fluorescence Immunoassay
Lateral Flow Immunochromatographic Assay
Other
Segment by Result Format
Quantitative
Semi Quantitative
Qualitative
Other
Segment by Application
Initial IBD Evaluation and Differential Diagnosis
Established IBD Disease Management
Other
Sales by Region
North America
U.S.
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
India
China Taiwan
Southeast Asia (Indonesia, Vietnam, Thailand)
Europe
Germany
France
U.K.
Italy
Russia
Central and South America
Brazil
Argentina
Rest of Central and South America
Middle East, Africa
Turkey
Egypt
GCC Countries
South Africa
Chapter Outline
Chapter 1: Defines the Fecal Calprotectin Assays study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential
Chapter 2: Offers current market state, projects global revenue and sales to 2032, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the manufacturer landscape: ranks by volume and revenue, analyzes profitability and pricing, maps production bases, details manufacturer performance by product type and evaluates concentration alongside M&A moves
Chapter 4: Unlocks high margin product segments: compares sales, revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities: evaluates sales, revenue, and pricing by Application, identifies emerging use cases, and profiles leading customers by region and by Application
Chapter 6: North America: breaks down sales and revenue by Application and country, profiles key manufacturers and assesses growth drivers and barriers
Chapter 7: Europe: analyses regional sales, revenue and market by Application and manufacturers, flagging drivers and barriers
Chapter 8: Asia Pacific: quantifies sales and revenue by Application, and region/country, profiles top manufacturers, and uncovers high potential expansion areas
Chapter 9: Central & South America: measures sales and revenue by Application, and country, profiles top manufacturers, and identifies investment opportunities and challenges
Chapter 10: Middle East and Africa: evaluates sales and revenue by Application, and country, profiles key manufacturers, and outlines investment prospects and market hurdles
Chapter 11: Profiles manufacturers in depth: details product specs, sales, revenue, margins; top manufactures 2025 sales breakdowns by product type, by Application, by sales region SWOT analysis, and recent strategic developments
Chapter 12: Supply chain: analyses upstream raw materials and suppliers, manufacturing footprint, regional production and cost, regulatory and technology, plus downstream channels and distributor roles
Chapter 13: Market dynamics: explores drivers, restraints, regulatory impacts, and risk mitigation strategies
Chapter 14: Actionable conclusions and strategic recommendations.
Why This Report
Beyond standard market data, this analysis provides a clear profitability roadmap, empowering you to:
Allocate capital strategically to high growth regions (Chapters 6-10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter 5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Secure your supply chain against disruptions through upstream and downstream visibility (Chapters 12 and 13).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.

ページTOPに戻る

Table of Contents

1 Study Coverage
1.1 Introduction to Fecal Calprotectin Assays: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Fecal Calprotectin Assays Market Size by Type, 2021 vs 2025 vs 2032
1.2.2 Enzyme Linked Immunosorbent Assay
1.2.3 Immunoturbidimetric Assay
1.2.4 Chemiluminescent Immunoassay
1.2.5 Fluorescence Immunoassay
1.2.6 Lateral Flow Immunochromatographic Assay
1.2.7 Other
1.3 Market Segmentation by Result Format
1.3.1 Global Fecal Calprotectin Assays Market Size by Result Format, 2021 vs 2025 vs 2032
1.3.2 Quantitative
1.3.3 Semi Quantitative
1.3.4 Qualitative
1.3.5 Other
1.4 Market Segmentation by Application
1.4.1 Global Fecal Calprotectin Assays Market Size by Application, 2021 vs 2025 vs 2032
1.4.2 Initial IBD Evaluation and Differential Diagnosis
1.4.3 Established IBD Disease Management
1.4.4 Other
1.5 Assumptions and Limitations
1.6 Study Objectives
1.7 Years Considered

2 Executive Summary
2.1 Global Fecal Calprotectin Assays Revenue Estimates and Forecasts (2021-2032)
2.2 Global Fecal Calprotectin Assays Revenue by Region
2.2.1 Revenue Comparison: 2021 vs 2025 vs 2032
2.2.2 Historical and Forecasted Revenue by Region (2021-2032)
2.2.3 Global Revenue-Based Market Share by Region (2021-2032)
2.3 Global Fecal Calprotectin Assays Sales Estimates and Forecasts (2021-2032)
2.4 Global Fecal Calprotectin Assays Sales by Region
2.4.1 Sales Comparison: 2021 vs 2025 vs 2032
2.4.2 Historical and Forecasted Sales by Region (2021-2032)
2.4.3 Emerging Market Focus: Growth Drivers & Investment Trends
2.4.4 Global Sales Market Share by Region (2021-2032)

3 Competitive Landscape
3.1 Global Fecal Calprotectin Assays Sales by Manufacturers
3.1.1 Global Sales Volume by Manufacturers (2021-2026)
3.1.2 Global Top 5 and Top 10 Manufacturers’Market Share by Sales Volume (2025)
3.2 Global Fecal Calprotectin Assays Manufacturer Revenue Rankings and Tiers
3.2.1 Global Revenue (Value) by Manufacturers (2021-2026)
3.2.2 Global Key Manufacturer Revenue Ranking (2024 vs. 2025)
3.2.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.3 Manufacturer Profitability Profiles and Pricing Strategies
3.3.1 Gross Margin by Top Manufacturer (2021 vs 2025)
3.3.2 Manufacturer-Level Price Trends (2021-2026)
3.4 Key Manufacturers Manufacturing Base and Headquarters
3.5 Key Manufacturers Market Share by Product Type
3.5.1 Enzyme Linked Immunosorbent Assay: Market Share by Key Manufacturers
3.5.2 Immunoturbidimetric Assay: Market Share by Key Manufacturers
3.5.3 Chemiluminescent Immunoassay: Market Share by Key Manufacturers
3.5.4 Fluorescence Immunoassay: Market Share by Key Manufacturers
3.5.5 Lateral Flow Immunochromatographic Assay: Market Share by Key Manufacturers
3.5.6 Other: Market Share by Key Manufacturers
3.6 Global Fecal Calprotectin Assays Market Concentration and Dynamics
3.6.1 Global Market Concentration
3.6.2 Entrant/Exit Impact Analysis
3.6.3 Strategic Moves: M&A, Capacity Expansion, R&D Investment

4 Product Segmentation
4.1 Global Fecal Calprotectin Assays Sales Performance by Type
4.1.1 Global Fecal Calprotectin Assays Sales Volume by Type (2021-2032)
4.1.2 Global Fecal Calprotectin Assays Revenue by Type (2021-2032)
4.1.3 Global Average Selling Price (ASP) Trends by Type (2021-2032)
4.2 Global Fecal Calprotectin Assays Sales Performance by Result Format
4.2.1 Global Fecal Calprotectin Assays Sales Volume by Result Format (2021-2032)
4.2.2 Global Fecal Calprotectin Assays Revenue by Result Format (2021-2032)
4.2.3 Global Average Selling Price (ASP) Trends by Result Format (2021-2032)
4.3 Product Technology Differentiation
4.4 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.4.1 High-Growth Niches and Adoption Drivers
4.4.2 Profitability Hotspots and Cost Drivers
4.4.3 Substitution Threats

5 Downstream Applications and Customers
5.1 Global Fecal Calprotectin Assays Sales by Application
5.1.1 Global Historical and Forecasted Sales by Application (2021-2032)
5.1.2 Global Sales Market Share by Application (2021-2032)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Global Fecal Calprotectin Assays Revenue by Application
5.2.1 Global Historical and Forecasted Revenue by Application (2021-2032)
5.2.2 Revenue-Based Market Share by Application (2021-2032)
5.3 Global Pricing Dynamics by Application (2021-2032)
5.4 Downstream Customer Analysis
5.4.1 Top Customers by Region
5.4.2 Top Customers by Application

6 North America
6.1 North America Sales Volume and Revenue (2021-2032)
6.2 North America Key Manufacturers Sales Revenue in 2025
6.3 North America Fecal Calprotectin Assays Sales and Revenue by Application (2021-2032)
6.4 North America Growth Accelerators and Market Barriers
6.5 North America Fecal Calprotectin Assays Market Size by Country
6.5.1 North America Revenue by Country
6.5.2 North America Sales Trends by Country
6.5.3 US
6.5.4 Canada
6.5.5 Mexico

7 Europe
7.1 Europe Sales Volume and Revenue (2021-2032)
7.2 Europe Key Manufacturers Sales Revenue in 2025
7.3 Europe Fecal Calprotectin Assays Sales and Revenue by Application (2021-2032)
7.4 Europe Growth Accelerators and Market Barriers
7.5 Europe Fecal Calprotectin Assays Market Size by Country
7.5.1 Europe Revenue by Country
7.5.2 Europe Sales Trends by Country
7.5.3 Germany
7.5.4 France
7.5.5 U.K.
7.5.6 Italy
7.5.7 Russia

8 Asia-Pacific
8.1 Asia-Pacific Sales Volume and Revenue (2021-2032)
8.2 Asia-Pacific Key Manufacturers Sales Revenue in 2025
8.3 Asia-Pacific Fecal Calprotectin Assays Sales and Revenue by Application (2021-2032)
8.4 Asia-Pacific Fecal Calprotectin Assays Market Size by Region
8.4.1 Asia-Pacific Revenue by Region
8.4.2 Asia-Pacific Sales Trends by Region
8.5 Asia-Pacific Growth Accelerators and Market Barriers
8.6 Southeast Asia
8.6.1 Southeast Asia Revenue by Country (2021 vs 2025 vs 2032)
8.6.2 Key Country Analysis: Indonesia, Vietnam, Thailand, Malaysia, Philippines
8.7 China
8.8 Japan
8.9 South Korea
8.10 China Taiwan
8.11 India

9 Central and South America
9.1 Central and South America Sales Volume and Revenue (2021-2032)
9.2 Central and South America Key Manufacturers Sales Revenue in 2025
9.3 Central and South America Fecal Calprotectin Assays Sales and Revenue by Application (2021-2032)
9.4 Central and South America Investment Opportunities and Key Challenges
9.5 Central and South America Fecal Calprotectin Assays Market Size by Country
9.5.1 Central and South America Revenue Trends by Country (2021 vs 2025 vs 2032)
9.5.2 Brazil
9.5.3 Argentina

10 Middle East and Africa
10.1 Middle East and Africa Sales Volume and Revenue (2021-2032)
10.2 Middle East and Africa Key Manufacturers Sales Revenue in 2025
10.3 Middle East and Africa Fecal Calprotectin Assays Sales and Revenue by Application (2021-2032)
10.4 Middle East and Africa Investment Opportunities and Key Challenges
10.5 Middle East and Africa Fecal Calprotectin Assays Market Size by Country
10.5.1 Middle East and Africa Revenue Trends by Country (2021 vs 2025 vs 2032)
10.5.2 GCC Countries
10.5.3 Turkey
10.5.4 Egypt
10.5.5 South Africa

11 Corporate Profile
11.1 BÜHLMANN Laboratories AG
11.1.1 BÜHLMANN Laboratories AG Corporation Information
11.1.2 BÜHLMANN Laboratories AG Business Overview
11.1.3 BÜHLMANN Laboratories AG Fecal Calprotectin Assays Product Models, Descriptions and Specifications
11.1.4 BÜHLMANN Laboratories AG Fecal Calprotectin Assays Sales, Price, Revenue and Gross Margin (2021-2026)
11.1.5 BÜHLMANN Laboratories AG Fecal Calprotectin Assays Sales by Product in 2025
11.1.6 BÜHLMANN Laboratories AG Fecal Calprotectin Assays Sales by Application in 2025
11.1.7 BÜHLMANN Laboratories AG Fecal Calprotectin Assays Sales by Geographic Area in 2025
11.1.8 BÜHLMANN Laboratories AG Fecal Calprotectin Assays SWOT Analysis
11.1.9 BÜHLMANN Laboratories AG Recent Developments
11.2 DiaSorin S.p.A.
11.2.1 DiaSorin S.p.A. Corporation Information
11.2.2 DiaSorin S.p.A. Business Overview
11.2.3 DiaSorin S.p.A. Fecal Calprotectin Assays Product Models, Descriptions and Specifications
11.2.4 DiaSorin S.p.A. Fecal Calprotectin Assays Sales, Price, Revenue and Gross Margin (2021-2026)
11.2.5 DiaSorin S.p.A. Fecal Calprotectin Assays Sales by Product in 2025
11.2.6 DiaSorin S.p.A. Fecal Calprotectin Assays Sales by Application in 2025
11.2.7 DiaSorin S.p.A. Fecal Calprotectin Assays Sales by Geographic Area in 2025
11.2.8 DiaSorin S.p.A. Fecal Calprotectin Assays SWOT Analysis
11.2.9 DiaSorin S.p.A. Recent Developments
11.3 Phadia AB
11.3.1 Phadia AB Corporation Information
11.3.2 Phadia AB Business Overview
11.3.3 Phadia AB Fecal Calprotectin Assays Product Models, Descriptions and Specifications
11.3.4 Phadia AB Fecal Calprotectin Assays Sales, Price, Revenue and Gross Margin (2021-2026)
11.3.5 Phadia AB Fecal Calprotectin Assays Sales by Product in 2025
11.3.6 Phadia AB Fecal Calprotectin Assays Sales by Application in 2025
11.3.7 Phadia AB Fecal Calprotectin Assays Sales by Geographic Area in 2025
11.3.8 Phadia AB Fecal Calprotectin Assays SWOT Analysis
11.3.9 Phadia AB Recent Developments
11.4 Inova Diagnostics, Inc.
11.4.1 Inova Diagnostics, Inc. Corporation Information
11.4.2 Inova Diagnostics, Inc. Business Overview
11.4.3 Inova Diagnostics, Inc. Fecal Calprotectin Assays Product Models, Descriptions and Specifications
11.4.4 Inova Diagnostics, Inc. Fecal Calprotectin Assays Sales, Price, Revenue and Gross Margin (2021-2026)
11.4.5 Inova Diagnostics, Inc. Fecal Calprotectin Assays Sales by Product in 2025
11.4.6 Inova Diagnostics, Inc. Fecal Calprotectin Assays Sales by Application in 2025
11.4.7 Inova Diagnostics, Inc. Fecal Calprotectin Assays Sales by Geographic Area in 2025
11.4.8 Inova Diagnostics, Inc. Fecal Calprotectin Assays SWOT Analysis
11.4.9 Inova Diagnostics, Inc. Recent Developments
11.5 EIKEN CHEMICAL CO., LTD.
11.5.1 EIKEN CHEMICAL CO., LTD. Corporation Information
11.5.2 EIKEN CHEMICAL CO., LTD. Business Overview
11.5.3 EIKEN CHEMICAL CO., LTD. Fecal Calprotectin Assays Product Models, Descriptions and Specifications
11.5.4 EIKEN CHEMICAL CO., LTD. Fecal Calprotectin Assays Sales, Price, Revenue and Gross Margin (2021-2026)
11.5.5 EIKEN CHEMICAL CO., LTD. Fecal Calprotectin Assays Sales by Product in 2025
11.5.6 EIKEN CHEMICAL CO., LTD. Fecal Calprotectin Assays Sales by Application in 2025
11.5.7 EIKEN CHEMICAL CO., LTD. Fecal Calprotectin Assays Sales by Geographic Area in 2025
11.5.8 EIKEN CHEMICAL CO., LTD. Fecal Calprotectin Assays SWOT Analysis
11.5.9 EIKEN CHEMICAL CO., LTD. Recent Developments
11.6 Revvity, Inc.
11.6.1 Revvity, Inc. Corporation Information
11.6.2 Revvity, Inc. Business Overview
11.6.3 Revvity, Inc. Fecal Calprotectin Assays Product Models, Descriptions and Specifications
11.6.4 Revvity, Inc. Fecal Calprotectin Assays Sales, Price, Revenue and Gross Margin (2021-2026)
11.6.5 Revvity, Inc. Recent Developments
11.7 R-Biopharm AG
11.7.1 R-Biopharm AG Corporation Information
11.7.2 R-Biopharm AG Business Overview
11.7.3 R-Biopharm AG Fecal Calprotectin Assays Product Models, Descriptions and Specifications
11.7.4 R-Biopharm AG Fecal Calprotectin Assays Sales, Price, Revenue and Gross Margin (2021-2026)
11.7.5 R-Biopharm AG Recent Developments
11.8 EUROSPITAL S.p.A.
11.8.1 EUROSPITAL S.p.A. Corporation Information
11.8.2 EUROSPITAL S.p.A. Business Overview
11.8.3 EUROSPITAL S.p.A. Fecal Calprotectin Assays Product Models, Descriptions and Specifications
11.8.4 EUROSPITAL S.p.A. Fecal Calprotectin Assays Sales, Price, Revenue and Gross Margin (2021-2026)
11.8.5 EUROSPITAL S.p.A. Recent Developments
11.9 SENTINEL CH. SpA
11.9.1 SENTINEL CH. SpA Corporation Information
11.9.2 SENTINEL CH. SpA Business Overview
11.9.3 SENTINEL CH. SpA Fecal Calprotectin Assays Product Models, Descriptions and Specifications
11.9.4 SENTINEL CH. SpA Fecal Calprotectin Assays Sales, Price, Revenue and Gross Margin (2021-2026)
11.9.5 SENTINEL CH. SpA Recent Developments
11.10 Calpro AS
11.10.1 Calpro AS Corporation Information
11.10.2 Calpro AS Business Overview
11.10.3 Calpro AS Fecal Calprotectin Assays Product Models, Descriptions and Specifications
11.10.4 Calpro AS Fecal Calprotectin Assays Sales, Price, Revenue and Gross Margin (2021-2026)
11.10.5 Calpro AS Recent Developments
11.11 ALPCO
11.11.1 ALPCO Corporation Information
11.11.2 ALPCO Business Overview
11.11.3 ALPCO Fecal Calprotectin Assays Product Models, Descriptions and Specifications
11.11.4 ALPCO Fecal Calprotectin Assays Sales, Price, Revenue and Gross Margin (2021-2026)
11.11.5 ALPCO Recent Developments
11.12 ORGENTEC Diagnostika GmbH
11.12.1 ORGENTEC Diagnostika GmbH Corporation Information
11.12.2 ORGENTEC Diagnostika GmbH Business Overview
11.12.3 ORGENTEC Diagnostika GmbH Fecal Calprotectin Assays Product Models, Descriptions and Specifications
11.12.4 ORGENTEC Diagnostika GmbH Fecal Calprotectin Assays Sales, Price, Revenue and Gross Margin (2021-2026)
11.12.5 ORGENTEC Diagnostika GmbH Recent Developments
11.13 BioSystems S.A.
11.13.1 BioSystems S.A. Corporation Information
11.13.2 BioSystems S.A. Business Overview
11.13.3 BioSystems S.A. Fecal Calprotectin Assays Product Models, Descriptions and Specifications
11.13.4 BioSystems S.A. Fecal Calprotectin Assays Sales, Price, Revenue and Gross Margin (2021-2026)
11.13.5 BioSystems S.A. Recent Developments
11.14 Boditech Med Inc.
11.14.1 Boditech Med Inc. Corporation Information
11.14.2 Boditech Med Inc. Business Overview
11.14.3 Boditech Med Inc. Fecal Calprotectin Assays Product Models, Descriptions and Specifications
11.14.4 Boditech Med Inc. Fecal Calprotectin Assays Sales, Price, Revenue and Gross Margin (2021-2026)
11.14.5 Boditech Med Inc. Recent Developments
11.15 Getein Biotech, Inc.
11.15.1 Getein Biotech, Inc. Corporation Information
11.15.2 Getein Biotech, Inc. Business Overview
11.15.3 Getein Biotech, Inc. Fecal Calprotectin Assays Product Models, Descriptions and Specifications
11.15.4 Getein Biotech, Inc. Fecal Calprotectin Assays Sales, Price, Revenue and Gross Margin (2021-2026)
11.15.5 Getein Biotech, Inc. Recent Developments
11.16 Hangzhou AllTest Biotech Co., Ltd.
11.16.1 Hangzhou AllTest Biotech Co., Ltd. Corporation Information
11.16.2 Hangzhou AllTest Biotech Co., Ltd. Business Overview
11.16.3 Hangzhou AllTest Biotech Co., Ltd. Fecal Calprotectin Assays Product Models, Descriptions and Specifications
11.16.4 Hangzhou AllTest Biotech Co., Ltd. Fecal Calprotectin Assays Sales, Price, Revenue and Gross Margin (2021-2026)
11.16.5 Hangzhou AllTest Biotech Co., Ltd. Recent Developments
11.17 Xiamen Wiz Biotech Co., Ltd.
11.17.1 Xiamen Wiz Biotech Co., Ltd. Corporation Information
11.17.2 Xiamen Wiz Biotech Co., Ltd. Business Overview
11.17.3 Xiamen Wiz Biotech Co., Ltd. Fecal Calprotectin Assays Product Models, Descriptions and Specifications
11.17.4 Xiamen Wiz Biotech Co., Ltd. Fecal Calprotectin Assays Sales, Price, Revenue and Gross Margin (2021-2026)
11.17.5 Xiamen Wiz Biotech Co., Ltd. Recent Developments
11.18 Sichuan Orienter Bioengineering Co., Ltd.
11.18.1 Sichuan Orienter Bioengineering Co., Ltd. Corporation Information
11.18.2 Sichuan Orienter Bioengineering Co., Ltd. Business Overview
11.18.3 Sichuan Orienter Bioengineering Co., Ltd. Fecal Calprotectin Assays Product Models, Descriptions and Specifications
11.18.4 Sichuan Orienter Bioengineering Co., Ltd. Fecal Calprotectin Assays Sales, Price, Revenue and Gross Margin (2021-2026)
11.18.5 Sichuan Orienter Bioengineering Co., Ltd. Recent Developments
11.19 Agappe Diagnostics Ltd.
11.19.1 Agappe Diagnostics Ltd. Corporation Information
11.19.2 Agappe Diagnostics Ltd. Business Overview
11.19.3 Agappe Diagnostics Ltd. Fecal Calprotectin Assays Product Models, Descriptions and Specifications
11.19.4 Agappe Diagnostics Ltd. Fecal Calprotectin Assays Sales, Price, Revenue and Gross Margin (2021-2026)
11.19.5 Agappe Diagnostics Ltd. Recent Developments
11.20 Immundiagnostik AG
11.20.1 Immundiagnostik AG Corporation Information
11.20.2 Immundiagnostik AG Business Overview
11.20.3 Immundiagnostik AG Fecal Calprotectin Assays Product Models, Descriptions and Specifications
11.20.4 Immundiagnostik AG Fecal Calprotectin Assays Sales, Price, Revenue and Gross Margin (2021-2026)
11.20.5 Immundiagnostik AG Recent Developments
11.21 Alfresa Pharma Corporation
11.21.1 Alfresa Pharma Corporation Corporation Information
11.21.2 Alfresa Pharma Corporation Business Overview
11.21.3 Alfresa Pharma Corporation Fecal Calprotectin Assays Product Models, Descriptions and Specifications
11.21.4 Alfresa Pharma Corporation Fecal Calprotectin Assays Sales, Price, Revenue and Gross Margin (2021-2026)
11.21.5 Alfresa Pharma Corporation Recent Developments
11.22 DiaSource ImmunoAssays S.A.
11.22.1 DiaSource ImmunoAssays S.A. Corporation Information
11.22.2 DiaSource ImmunoAssays S.A. Business Overview
11.22.3 DiaSource ImmunoAssays S.A. Fecal Calprotectin Assays Product Models, Descriptions and Specifications
11.22.4 DiaSource ImmunoAssays S.A. Fecal Calprotectin Assays Sales, Price, Revenue and Gross Margin (2021-2026)
11.22.5 DiaSource ImmunoAssays S.A. Recent Developments
11.23 Epitope Diagnostics, Inc.
11.23.1 Epitope Diagnostics, Inc. Corporation Information
11.23.2 Epitope Diagnostics, Inc. Business Overview
11.23.3 Epitope Diagnostics, Inc. Fecal Calprotectin Assays Product Models, Descriptions and Specifications
11.23.4 Epitope Diagnostics, Inc. Fecal Calprotectin Assays Sales, Price, Revenue and Gross Margin (2021-2026)
11.23.5 Epitope Diagnostics, Inc. Recent Developments
11.24 ScheBo Biotech AG
11.24.1 ScheBo Biotech AG Corporation Information
11.24.2 ScheBo Biotech AG Business Overview
11.24.3 ScheBo Biotech AG Fecal Calprotectin Assays Product Models, Descriptions and Specifications
11.24.4 ScheBo Biotech AG Fecal Calprotectin Assays Sales, Price, Revenue and Gross Margin (2021-2026)
11.24.5 ScheBo Biotech AG Recent Developments
11.25 Vitassay Healthcare, S.L.U.
11.25.1 Vitassay Healthcare, S.L.U. Corporation Information
11.25.2 Vitassay Healthcare, S.L.U. Business Overview
11.25.3 Vitassay Healthcare, S.L.U. Fecal Calprotectin Assays Product Models, Descriptions and Specifications
11.25.4 Vitassay Healthcare, S.L.U. Fecal Calprotectin Assays Sales, Price, Revenue and Gross Margin (2021-2026)
11.25.5 Vitassay Healthcare, S.L.U. Recent Developments
11.26 Certest Biotec S.L.
11.26.1 Certest Biotec S.L. Corporation Information
11.26.2 Certest Biotec S.L. Business Overview
11.26.3 Certest Biotec S.L. Fecal Calprotectin Assays Product Models, Descriptions and Specifications
11.26.4 Certest Biotec S.L. Fecal Calprotectin Assays Sales, Price, Revenue and Gross Margin (2021-2026)
11.26.5 Certest Biotec S.L. Recent Developments
11.27 VEDA.LAB
11.27.1 VEDA.LAB Corporation Information
11.27.2 VEDA.LAB Business Overview
11.27.3 VEDA.LAB Fecal Calprotectin Assays Product Models, Descriptions and Specifications
11.27.4 VEDA.LAB Fecal Calprotectin Assays Sales, Price, Revenue and Gross Margin (2021-2026)
11.27.5 VEDA.LAB Recent Developments
11.28 Shijiazhuang Hipro Biotechnology Co., Ltd.
11.28.1 Shijiazhuang Hipro Biotechnology Co., Ltd. Corporation Information
11.28.2 Shijiazhuang Hipro Biotechnology Co., Ltd. Business Overview
11.28.3 Shijiazhuang Hipro Biotechnology Co., Ltd. Fecal Calprotectin Assays Product Models, Descriptions and Specifications
11.28.4 Shijiazhuang Hipro Biotechnology Co., Ltd. Fecal Calprotectin Assays Sales, Price, Revenue and Gross Margin (2021-2026)
11.28.5 Shijiazhuang Hipro Biotechnology Co., Ltd. Recent Developments
11.29 Guangzhou Forreal Biotechnology Co., Ltd.
11.29.1 Guangzhou Forreal Biotechnology Co., Ltd. Corporation Information
11.29.2 Guangzhou Forreal Biotechnology Co., Ltd. Business Overview
11.29.3 Guangzhou Forreal Biotechnology Co., Ltd. Fecal Calprotectin Assays Product Models, Descriptions and Specifications
11.29.4 Guangzhou Forreal Biotechnology Co., Ltd. Fecal Calprotectin Assays Sales, Price, Revenue and Gross Margin (2021-2026)
11.29.5 Guangzhou Forreal Biotechnology Co., Ltd. Recent Developments
11.30 AccuBioTech Co., Ltd.
11.30.1 AccuBioTech Co., Ltd. Corporation Information
11.30.2 AccuBioTech Co., Ltd. Business Overview
11.30.3 AccuBioTech Co., Ltd. Fecal Calprotectin Assays Product Models, Descriptions and Specifications
11.30.4 AccuBioTech Co., Ltd. Fecal Calprotectin Assays Sales, Price, Revenue and Gross Margin (2021-2026)
11.30.5 AccuBioTech Co., Ltd. Recent Developments
11.31 Zhejiang Wantaifu Biotechnology Co., Ltd.
11.31.1 Zhejiang Wantaifu Biotechnology Co., Ltd. Corporation Information
11.31.2 Zhejiang Wantaifu Biotechnology Co., Ltd. Business Overview
11.31.3 Zhejiang Wantaifu Biotechnology Co., Ltd. Fecal Calprotectin Assays Product Models, Descriptions and Specifications
11.31.4 Zhejiang Wantaifu Biotechnology Co., Ltd. Fecal Calprotectin Assays Sales, Price, Revenue and Gross Margin (2021-2026)
11.31.5 Zhejiang Wantaifu Biotechnology Co., Ltd. Recent Developments
11.32 Famid Biomedical Technology Tianjin Co., Ltd.
11.32.1 Famid Biomedical Technology Tianjin Co., Ltd. Corporation Information
11.32.2 Famid Biomedical Technology Tianjin Co., Ltd. Business Overview
11.32.3 Famid Biomedical Technology Tianjin Co., Ltd. Fecal Calprotectin Assays Product Models, Descriptions and Specifications
11.32.4 Famid Biomedical Technology Tianjin Co., Ltd. Fecal Calprotectin Assays Sales, Price, Revenue and Gross Margin (2021-2026)
11.32.5 Famid Biomedical Technology Tianjin Co., Ltd. Recent Developments

12 Value Chain and Supply-Chain Analysis
12.1 Fecal Calprotectin Assays Industry Chain
12.2 Fecal Calprotectin Assays Upstream Materials Analysis
12.2.1 Raw Materials
12.2.2 Key Suppliers Market Share & Risk Assessment
12.3 Fecal Calprotectin Assays Integrated Production Analysis
12.3.1 Manufacturing Footprint Analysis
12.3.2 Regional Production Market Share (2021-2032)
12.3.3 Regulatory and Trade Policy Impact on Production
12.3.4 Production Technology Overview
12.3.5 Regional Cost Drivers
12.4 Fecal Calprotectin Assays Sales Channels and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors

13 Fecal Calprotectin Assays Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
13.4 Impact of U.S. Tariffs

14 Key Findings in the Global Fecal Calprotectin Assays Study

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details

ページTOPに戻る

List of Tables/Graphs

List of Tables
Table 1. Global Fecal Calprotectin Assays Market Size Growth Rate by Type, 2021 vs 2025 vs 2032 (US$ Million)
Table 2. Global Fecal Calprotectin Assays Market Size Growth Rate by Result Format, 2021 vs 2025 vs 2032 (US$ Million)
Table 3. Global Fecal Calprotectin Assays Market Size Growth Rate by Application, 2021 vs 2025 vs 2032 (US$ Million)
Table 4. Global Fecal Calprotectin Assays Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 5. Global Fecal Calprotectin Assays Revenue by Region (US$ Million), 2021-2026
Table 6. Global Fecal Calprotectin Assays Revenue by Region (US$ Million), 2027-2032
Table 7. Global Fecal Calprotectin Assays Sales Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (K Units)
Table 8. Global Fecal Calprotectin Assays Sales by Region (K Units), 2021-2026
Table 9. Global Fecal Calprotectin Assays Sales by Region (K Units), 2027-2032
Table 10. Emerging Market Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 11. Global Fecal Calprotectin Assays Sales by Manufacturers (K Units), 2021-2026
Table 12. Global Fecal Calprotectin Assays Sales Share by Manufacturers (2021-2026)
Table 13. Global Fecal Calprotectin Assays Revenue by Manufacturers (US$ Million), 2021-2026
Table 14. Global Fecal Calprotectin Assays Revenue-Based Market Share by Manufacturers (2021-2026)
Table 15. Global Key Manufacturers’Ranking Shift (2024 vs. 2025) (Based on Revenue)
Table 16. Global Manufacturer by Tier (Tier 1, Tier 2, and Tier 3), based on Fecal Calprotectin Assays Revenue, 2025
Table 17. Global Fecal Calprotectin Assays Average Gross Margin (%) by Manufacturer (2021 vs 2025)
Table 18. Global Fecal Calprotectin Assays Average Selling Price (ASP) by Manufacturers (US$/Unit), 2021-2026
Table 19. Key Manufacturers Fecal Calprotectin Assays Manufacturing Base and Headquarters
Table 20. Global Fecal Calprotectin Assays Market Concentration Ratio (CR5)
Table 21. Key Market Entrant/Exit (2021-2025) – Drivers & Impact Analysis
Table 22. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 23. Global Fecal Calprotectin Assays Sales Volume by Type (K Units), 2021-2026
Table 24. Global Fecal Calprotectin Assays Sales Volume by Type (K Units), 2027-2032
Table 25. Global Fecal Calprotectin Assays Revenue by Type (US$ Million), 2021-2026
Table 26. Global Fecal Calprotectin Assays Revenue by Type (US$ Million), 2027-2032
Table 27. Global Fecal Calprotectin Assays Sales Volume by Result Format (K Units), 2021-2026
Table 28. Global Fecal Calprotectin Assays Sales Volume by Result Format (K Units), 2027-2032
Table 29. Global Fecal Calprotectin Assays Revenue by Result Format (US$ Million), 2021-2026
Table 30. Global Fecal Calprotectin Assays Revenue by Result Format (US$ Million), 2027-2032
Table 31. Technical Specifications by Key Product Type
Table 32. Global Fecal Calprotectin Assays Sales by Application (K Units), 2021-2026
Table 33. Global Fecal Calprotectin Assays Sales by Application (K Units), 2027-2032
Table 34. Fecal Calprotectin Assays High-Growth Sectors Demand CAGR (2026-2032)
Table 35. Global Fecal Calprotectin Assays Revenue by Application (US$ Million), 2021-2026
Table 36. Global Fecal Calprotectin Assays Revenue by Application (US$ Million), 2027-2032
Table 37. Top Customers by Region
Table 38. Top Customers by Application
Table 39. North America Fecal Calprotectin Assays Growth Accelerators and Market Barriers
Table 40. North America Fecal Calprotectin Assays Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 41. North America Fecal Calprotectin Assays Sales (K Units) by Country (2021 vs 2025 vs 2032)
Table 42. Europe Fecal Calprotectin Assays Growth Accelerators and Market Barriers
Table 43. Europe Fecal Calprotectin Assays Revenue Grow Rate (CAGR) by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 44. Europe Fecal Calprotectin Assays Sales (K Units) by Country (2021 vs 2025 vs 2032)
Table 45. Asia-Pacific Fecal Calprotectin Assays Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 46. Asia-Pacific Fecal Calprotectin Assays Sales (K Units) by Country (2021 vs 2025 vs 2032)
Table 47. Asia-Pacific Fecal Calprotectin Assays Growth Accelerators and Market Barriers
Table 48. Southeast Asia Fecal Calprotectin Assays Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 49. Central and South America Fecal Calprotectin Assays Investment Opportunities and Key Challenges
Table 50. Central and South America Fecal Calprotectin Assays Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 51. Middle East and Africa Fecal Calprotectin Assays Investment Opportunities and Key Challenges
Table 52. Middle East and Africa Fecal Calprotectin Assays Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 53. BÜHLMANN Laboratories AG Corporation Information
Table 54. BÜHLMANN Laboratories AG Description and Major Businesses
Table 55. BÜHLMANN Laboratories AG Product Models, Descriptions and Specifications
Table 56. BÜHLMANN Laboratories AG Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 57. BÜHLMANN Laboratories AG Sales Value Proportion by Product in 2025
Table 58. BÜHLMANN Laboratories AG Sales Value Proportion by Application in 2025
Table 59. BÜHLMANN Laboratories AG Sales Value Proportion by Geographic Area in 2025
Table 60. BÜHLMANN Laboratories AG Fecal Calprotectin Assays SWOT Analysis
Table 61. BÜHLMANN Laboratories AG Recent Developments
Table 62. DiaSorin S.p.A. Corporation Information
Table 63. DiaSorin S.p.A. Description and Major Businesses
Table 64. DiaSorin S.p.A. Product Models, Descriptions and Specifications
Table 65. DiaSorin S.p.A. Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 66. DiaSorin S.p.A. Sales Value Proportion by Product in 2025
Table 67. DiaSorin S.p.A. Sales Value Proportion by Application in 2025
Table 68. DiaSorin S.p.A. Sales Value Proportion by Geographic Area in 2025
Table 69. DiaSorin S.p.A. Fecal Calprotectin Assays SWOT Analysis
Table 70. DiaSorin S.p.A. Recent Developments
Table 71. Phadia AB Corporation Information
Table 72. Phadia AB Description and Major Businesses
Table 73. Phadia AB Product Models, Descriptions and Specifications
Table 74. Phadia AB Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 75. Phadia AB Sales Value Proportion by Product in 2025
Table 76. Phadia AB Sales Value Proportion by Application in 2025
Table 77. Phadia AB Sales Value Proportion by Geographic Area in 2025
Table 78. Phadia AB Fecal Calprotectin Assays SWOT Analysis
Table 79. Phadia AB Recent Developments
Table 80. Inova Diagnostics, Inc. Corporation Information
Table 81. Inova Diagnostics, Inc. Description and Major Businesses
Table 82. Inova Diagnostics, Inc. Product Models, Descriptions and Specifications
Table 83. Inova Diagnostics, Inc. Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 84. Inova Diagnostics, Inc. Sales Value Proportion by Product in 2025
Table 85. Inova Diagnostics, Inc. Sales Value Proportion by Application in 2025
Table 86. Inova Diagnostics, Inc. Sales Value Proportion by Geographic Area in 2025
Table 87. Inova Diagnostics, Inc. Fecal Calprotectin Assays SWOT Analysis
Table 88. Inova Diagnostics, Inc. Recent Developments
Table 89. EIKEN CHEMICAL CO., LTD. Corporation Information
Table 90. EIKEN CHEMICAL CO., LTD. Description and Major Businesses
Table 91. EIKEN CHEMICAL CO., LTD. Product Models, Descriptions and Specifications
Table 92. EIKEN CHEMICAL CO., LTD. Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 93. EIKEN CHEMICAL CO., LTD. Sales Value Proportion by Product in 2025
Table 94. EIKEN CHEMICAL CO., LTD. Sales Value Proportion by Application in 2025
Table 95. EIKEN CHEMICAL CO., LTD. Sales Value Proportion by Geographic Area in 2025
Table 96. EIKEN CHEMICAL CO., LTD. Fecal Calprotectin Assays SWOT Analysis
Table 97. EIKEN CHEMICAL CO., LTD. Recent Developments
Table 98. Revvity, Inc. Corporation Information
Table 99. Revvity, Inc. Description and Major Businesses
Table 100. Revvity, Inc. Product Models, Descriptions and Specifications
Table 101. Revvity, Inc. Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 102. Revvity, Inc. Recent Developments
Table 103. R-Biopharm AG Corporation Information
Table 104. R-Biopharm AG Description and Major Businesses
Table 105. R-Biopharm AG Product Models, Descriptions and Specifications
Table 106. R-Biopharm AG Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 107. R-Biopharm AG Recent Developments
Table 108. EUROSPITAL S.p.A. Corporation Information
Table 109. EUROSPITAL S.p.A. Description and Major Businesses
Table 110. EUROSPITAL S.p.A. Product Models, Descriptions and Specifications
Table 111. EUROSPITAL S.p.A. Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 112. EUROSPITAL S.p.A. Recent Developments
Table 113. SENTINEL CH. SpA Corporation Information
Table 114. SENTINEL CH. SpA Description and Major Businesses
Table 115. SENTINEL CH. SpA Product Models, Descriptions and Specifications
Table 116. SENTINEL CH. SpA Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 117. SENTINEL CH. SpA Recent Developments
Table 118. Calpro AS Corporation Information
Table 119. Calpro AS Description and Major Businesses
Table 120. Calpro AS Product Models, Descriptions and Specifications
Table 121. Calpro AS Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 122. Calpro AS Recent Developments
Table 123. ALPCO Corporation Information
Table 124. ALPCO Description and Major Businesses
Table 125. ALPCO Product Models, Descriptions and Specifications
Table 126. ALPCO Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 127. ALPCO Recent Developments
Table 128. ORGENTEC Diagnostika GmbH Corporation Information
Table 129. ORGENTEC Diagnostika GmbH Description and Major Businesses
Table 130. ORGENTEC Diagnostika GmbH Product Models, Descriptions and Specifications
Table 131. ORGENTEC Diagnostika GmbH Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 132. ORGENTEC Diagnostika GmbH Recent Developments
Table 133. BioSystems S.A. Corporation Information
Table 134. BioSystems S.A. Description and Major Businesses
Table 135. BioSystems S.A. Product Models, Descriptions and Specifications
Table 136. BioSystems S.A. Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 137. BioSystems S.A. Recent Developments
Table 138. Boditech Med Inc. Corporation Information
Table 139. Boditech Med Inc. Description and Major Businesses
Table 140. Boditech Med Inc. Product Models, Descriptions and Specifications
Table 141. Boditech Med Inc. Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 142. Boditech Med Inc. Recent Developments
Table 143. Getein Biotech, Inc. Corporation Information
Table 144. Getein Biotech, Inc. Description and Major Businesses
Table 145. Getein Biotech, Inc. Product Models, Descriptions and Specifications
Table 146. Getein Biotech, Inc. Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 147. Getein Biotech, Inc. Recent Developments
Table 148. Hangzhou AllTest Biotech Co., Ltd. Corporation Information
Table 149. Hangzhou AllTest Biotech Co., Ltd. Description and Major Businesses
Table 150. Hangzhou AllTest Biotech Co., Ltd. Product Models, Descriptions and Specifications
Table 151. Hangzhou AllTest Biotech Co., Ltd. Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 152. Hangzhou AllTest Biotech Co., Ltd. Recent Developments
Table 153. Xiamen Wiz Biotech Co., Ltd. Corporation Information
Table 154. Xiamen Wiz Biotech Co., Ltd. Description and Major Businesses
Table 155. Xiamen Wiz Biotech Co., Ltd. Product Models, Descriptions and Specifications
Table 156. Xiamen Wiz Biotech Co., Ltd. Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 157. Xiamen Wiz Biotech Co., Ltd. Recent Developments
Table 158. Sichuan Orienter Bioengineering Co., Ltd. Corporation Information
Table 159. Sichuan Orienter Bioengineering Co., Ltd. Description and Major Businesses
Table 160. Sichuan Orienter Bioengineering Co., Ltd. Product Models, Descriptions and Specifications
Table 161. Sichuan Orienter Bioengineering Co., Ltd. Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 162. Sichuan Orienter Bioengineering Co., Ltd. Recent Developments
Table 163. Agappe Diagnostics Ltd. Corporation Information
Table 164. Agappe Diagnostics Ltd. Description and Major Businesses
Table 165. Agappe Diagnostics Ltd. Product Models, Descriptions and Specifications
Table 166. Agappe Diagnostics Ltd. Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 167. Agappe Diagnostics Ltd. Recent Developments
Table 168. Immundiagnostik AG Corporation Information
Table 169. Immundiagnostik AG Description and Major Businesses
Table 170. Immundiagnostik AG Product Models, Descriptions and Specifications
Table 171. Immundiagnostik AG Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 172. Immundiagnostik AG Recent Developments
Table 173. Alfresa Pharma Corporation Corporation Information
Table 174. Alfresa Pharma Corporation Description and Major Businesses
Table 175. Alfresa Pharma Corporation Product Models, Descriptions and Specifications
Table 176. Alfresa Pharma Corporation Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 177. Alfresa Pharma Corporation Recent Developments
Table 178. DiaSource ImmunoAssays S.A. Corporation Information
Table 179. DiaSource ImmunoAssays S.A. Description and Major Businesses
Table 180. DiaSource ImmunoAssays S.A. Product Models, Descriptions and Specifications
Table 181. DiaSource ImmunoAssays S.A. Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 182. DiaSource ImmunoAssays S.A. Recent Developments
Table 183. Epitope Diagnostics, Inc. Corporation Information
Table 184. Epitope Diagnostics, Inc. Description and Major Businesses
Table 185. Epitope Diagnostics, Inc. Product Models, Descriptions and Specifications
Table 186. Epitope Diagnostics, Inc. Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 187. Epitope Diagnostics, Inc. Recent Developments
Table 188. ScheBo Biotech AG Corporation Information
Table 189. ScheBo Biotech AG Description and Major Businesses
Table 190. ScheBo Biotech AG Product Models, Descriptions and Specifications
Table 191. ScheBo Biotech AG Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 192. ScheBo Biotech AG Recent Developments
Table 193. Vitassay Healthcare, S.L.U. Corporation Information
Table 194. Vitassay Healthcare, S.L.U. Description and Major Businesses
Table 195. Vitassay Healthcare, S.L.U. Product Models, Descriptions and Specifications
Table 196. Vitassay Healthcare, S.L.U. Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 197. Vitassay Healthcare, S.L.U. Recent Developments
Table 198. Certest Biotec S.L. Corporation Information
Table 199. Certest Biotec S.L. Description and Major Businesses
Table 200. Certest Biotec S.L. Product Models, Descriptions and Specifications
Table 201. Certest Biotec S.L. Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 202. Certest Biotec S.L. Recent Developments
Table 203. VEDA.LAB Corporation Information
Table 204. VEDA.LAB Description and Major Businesses
Table 205. VEDA.LAB Product Models, Descriptions and Specifications
Table 206. VEDA.LAB Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 207. VEDA.LAB Recent Developments
Table 208. Shijiazhuang Hipro Biotechnology Co., Ltd. Corporation Information
Table 209. Shijiazhuang Hipro Biotechnology Co., Ltd. Description and Major Businesses
Table 210. Shijiazhuang Hipro Biotechnology Co., Ltd. Product Models, Descriptions and Specifications
Table 211. Shijiazhuang Hipro Biotechnology Co., Ltd. Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 212. Shijiazhuang Hipro Biotechnology Co., Ltd. Recent Developments
Table 213. Guangzhou Forreal Biotechnology Co., Ltd. Corporation Information
Table 214. Guangzhou Forreal Biotechnology Co., Ltd. Description and Major Businesses
Table 215. Guangzhou Forreal Biotechnology Co., Ltd. Product Models, Descriptions and Specifications
Table 216. Guangzhou Forreal Biotechnology Co., Ltd. Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 217. Guangzhou Forreal Biotechnology Co., Ltd. Recent Developments
Table 218. AccuBioTech Co., Ltd. Corporation Information
Table 219. AccuBioTech Co., Ltd. Description and Major Businesses
Table 220. AccuBioTech Co., Ltd. Product Models, Descriptions and Specifications
Table 221. AccuBioTech Co., Ltd. Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 222. AccuBioTech Co., Ltd. Recent Developments
Table 223. Zhejiang Wantaifu Biotechnology Co., Ltd. Corporation Information
Table 224. Zhejiang Wantaifu Biotechnology Co., Ltd. Description and Major Businesses
Table 225. Zhejiang Wantaifu Biotechnology Co., Ltd. Product Models, Descriptions and Specifications
Table 226. Zhejiang Wantaifu Biotechnology Co., Ltd. Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 227. Zhejiang Wantaifu Biotechnology Co., Ltd. Recent Developments
Table 228. Famid Biomedical Technology Tianjin Co., Ltd. Corporation Information
Table 229. Famid Biomedical Technology Tianjin Co., Ltd. Description and Major Businesses
Table 230. Famid Biomedical Technology Tianjin Co., Ltd. Product Models, Descriptions and Specifications
Table 231. Famid Biomedical Technology Tianjin Co., Ltd. Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 232. Famid Biomedical Technology Tianjin Co., Ltd. Recent Developments
Table 233. Key Raw Materials Distribution
Table 234. Raw Materials Key Suppliers
Table 235. Critical Raw Material Supplier Concentration (2025) & Risk Index
Table 236. Milestones in Production Technology Evolution
Table 237. Distributors List
Table 238. Market Trends and Market Evolution
Table 239. Market Drivers and Opportunities
Table 240. Market Challenges, Risks, and Restraints
Table 241. Research Programs/Design for This Report
Table 242. Key Data Information from Secondary Sources
Table 243. Key Data Information from Primary Sources

List of Figures
Figure 1. Fecal Calprotectin Assays Product Picture
Figure 2. Global Fecal Calprotectin Assays Market Size Growth Rate by Type, 2021 vs 2025 vs 2032 (US$ Million)
Figure 3. Enzyme Linked Immunosorbent Assay Product Picture
Figure 4. Immunoturbidimetric Assay Product Picture
Figure 5. Chemiluminescent Immunoassay Product Picture
Figure 6. Fluorescence Immunoassay Product Picture
Figure 7. Lateral Flow Immunochromatographic Assay Product Picture
Figure 8. Other Product Picture
Figure 9. Global Fecal Calprotectin Assays Market Size Growth Rate by Result Format, 2021 vs 2025 vs 2032 (US$ Million)
Figure 10. Quantitative Product Picture
Figure 11. Semi Quantitative Product Picture
Figure 12. Qualitative Product Picture
Figure 13. Other Product Picture
Figure 14. Global Fecal Calprotectin Assays Market Size Growth Rate by Application, 2021 vs 2025 vs 2032 (US$ Million)
Figure 15. Initial IBD Evaluation and Differential Diagnosis
Figure 16. Established IBD Disease Management
Figure 17. Other
Figure 18. Fecal Calprotectin Assays Report Years Considered
Figure 19. Global Fecal Calprotectin Assays Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 20. Global Fecal Calprotectin Assays Revenue (US$ Million), 2021-2032
Figure 21. Global Fecal Calprotectin Assays Revenue (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Figure 22. Global Fecal Calprotectin Assays Revenue-Based Market Share by Region (2021-2032)
Figure 23. Global Fecal Calprotectin Assays Sales (K Units), 2021-2032
Figure 24. Global Fecal Calprotectin Assays Sales (CAGR) by Region: 2021 vs 2025 vs 2032 (K Units)
Figure 25. Global Fecal Calprotectin Assays Sales Market Share by Region (2021-2032)
Figure 26. Top 5 and Top 10 Manufacturers Fecal Calprotectin Assays Sales Volume Market Share in 2025
Figure 27. Global Fecal Calprotectin Assays Revenue-Based Market Share Ranking (2025)
Figure 28. Tier Distribution by Revenue Contribution (2021 vs 2025)
Figure 29. Enzyme Linked Immunosorbent Assay Revenue-Based Market Share by Manufacturer in 2025
Figure 30. Immunoturbidimetric Assay Revenue-Based Market Share by Manufacturer in 2025
Figure 31. Chemiluminescent Immunoassay Revenue-Based Market Share by Manufacturer in 2025
Figure 32. Fluorescence Immunoassay Revenue-Based Market Share by Manufacturer in 2025
Figure 33. Lateral Flow Immunochromatographic Assay Revenue-Based Market Share by Manufacturer in 2025
Figure 34. Other Revenue-Based Market Share by Manufacturer in 2025
Figure 35. Global Fecal Calprotectin Assays Sales Volume-Based Market Share by Type (2021-2032)
Figure 36. Global Fecal Calprotectin Assays Revenue-Based Market Share by Type (2021-2032)
Figure 37. Global Fecal Calprotectin Assays ASP by Type (US$/Unit), 2021-2032
Figure 38. Global Fecal Calprotectin Assays Sales Volume-Based Market Share by Result Format (2021-2032)
Figure 39. Global Fecal Calprotectin Assays Revenue-Based Market Share by Result Format (2021-2032)
Figure 40. Global Fecal Calprotectin Assays ASP by Result Format (US$/Unit), 2021-2032
Figure 41. Global Fecal Calprotectin Assays Revenue-Based Market Share (2021-2032)
Figure 42. Global Fecal Calprotectin Assays Sales Market Share by Application (2021-2032)
Figure 43. Global Fecal Calprotectin Assays Revenue-Based Market Share by Application (2021-2032)
Figure 44. Global Fecal Calprotectin Assays ASP by Application (US$/Unit), 2021-2032
Figure 45. North America Fecal Calprotectin Assays Sales YoY (K Units), 2021-2032
Figure 46. North America Fecal Calprotectin Assays Revenue YoY (US$ Million), 2021-2032
Figure 47. North America Top 5 Manufacturers Fecal Calprotectin Assays Sales Revenue (US$ Million) in 2025
Figure 48. North America Fecal Calprotectin Assays Sales Volume (K Units) by Application (2021-2032)
Figure 49. North America Fecal Calprotectin Assays Sales Revenue (US$ Million) by Application (2021-2032)
Figure 50. US Fecal Calprotectin Assays Revenue (US$ Million), 2021-2032
Figure 51. Canada Fecal Calprotectin Assays Revenue (US$ Million), 2021-2032
Figure 52. Mexico Fecal Calprotectin Assays Revenue (US$ Million), 2021-2032
Figure 53. Europe Fecal Calprotectin Assays Sales YoY (K Units), 2021-2032
Figure 54. Europe Fecal Calprotectin Assays Revenue YoY (US$ Million), 2021-2032
Figure 55. Europe Top 5 Manufacturers Fecal Calprotectin Assays Sales Revenue (US$ Million) in 2025
Figure 56. Europe Fecal Calprotectin Assays Sales Volume (K Units) by Application (2021-2032)
Figure 57. Europe Fecal Calprotectin Assays Sales Revenue (US$ Million) by Application (2021-2032)
Figure 58. Germany Fecal Calprotectin Assays Revenue (US$ Million), 2021-2032
Figure 59. France Fecal Calprotectin Assays Revenue (US$ Million), 2021-2032
Figure 60. U.K. Fecal Calprotectin Assays Revenue (US$ Million), 2021-2032
Figure 61. Italy Fecal Calprotectin Assays Revenue (US$ Million), 2021-2032
Figure 62. Russia Fecal Calprotectin Assays Revenue (US$ Million), 2021-2032
Figure 63. Asia-Pacific Fecal Calprotectin Assays Sales YoY (K Units), 2021-2032
Figure 64. Asia-Pacific Fecal Calprotectin Assays Revenue YoY (US$ Million), 2021-2032
Figure 65. Asia-Pacific Top 8 Manufacturers Fecal Calprotectin Assays Sales Revenue (US$ Million) in 2025
Figure 66. Asia-Pacific Fecal Calprotectin Assays Sales Volume (K Units) by Application (2021-2032)
Figure 67. Asia-Pacific Fecal Calprotectin Assays Sales Revenue (US$ Million) by Application (2021-2032)
Figure 68. Indonesia Fecal Calprotectin Assays Revenue (US$ Million), 2021-2032
Figure 69. Japan Fecal Calprotectin Assays Revenue (US$ Million), 2021-2032
Figure 70. South Korea Fecal Calprotectin Assays Revenue (US$ Million), 2021-2032
Figure 71. China Taiwan Fecal Calprotectin Assays Revenue (US$ Million), 2021-2032
Figure 72. India Fecal Calprotectin Assays Revenue (US$ Million), 2021-2032
Figure 73. Central and South America Fecal Calprotectin Assays Sales YoY (K Units), 2021-2032
Figure 74. Central and South America Fecal Calprotectin Assays Revenue YoY (US$ Million), 2021-2032
Figure 75. Central and South America Top 5 Manufacturers Fecal Calprotectin Assays Sales Revenue (US$ Million) in 2025
Figure 76. Central and South America Fecal Calprotectin Assays Sales Volume (K Units) by Application (2021-2032)
Figure 77. Central and South America Fecal Calprotectin Assays Sales Revenue (US$ Million) by Application (2021-2032)
Figure 78. Brazil Fecal Calprotectin Assays Revenue (US$ Million), 2021-2032
Figure 79. Argentina Fecal Calprotectin Assays Revenue (US$ Million), 2021-2032
Figure 80. Middle East, and Africa Fecal Calprotectin Assays Sales YoY (K Units), 2021-2032
Figure 81. Middle East and Africa Fecal Calprotectin Assays Revenue YoY (US$ Million), 2021-2032
Figure 82. Middle East and Africa Top 5 Manufacturers Fecal Calprotectin Assays Sales Revenue (US$ Million) in 2025
Figure 83. Middle East and Africa Fecal Calprotectin Assays Sales Volume (K Units) by Application (2021-2032)
Figure 84. Middle East and Africa Fecal Calprotectin Assays Sales Revenue (US$ Million) by Application (2021-2032)
Figure 85. GCC Countries Fecal Calprotectin Assays Revenue (US$ Million), 2021-2032
Figure 86. Turkey Fecal Calprotectin Assays Revenue (US$ Million), 2021-2032
Figure 87. Egypt Fecal Calprotectin Assays Revenue (US$ Million), 2021-2032
Figure 88. South Africa Fecal Calprotectin Assays Revenue (US$ Million), 2021-2032
Figure 89. Fecal Calprotectin Assays Industry Chain Mapping
Figure 90. Regional Fecal Calprotectin Assays Manufacturing Base Distribution (%)
Figure 91. Global Fecal Calprotectin Assays Production Market Share by Region (2021-2032)
Figure 92. Fecal Calprotectin Assays Production Process
Figure 93. Regional Fecal Calprotectin Assays Production Cost Structure
Figure 94. Channels of Distribution (Direct Vs Distribution)
Figure 95. Bottom-up and Top-down Approaches for This Report
Figure 96. Data Triangulation
Figure 97. Key Executives Interviewed